NCT05468359 2026-03-16
Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients
St. Jude Children's Research Hospital
Phase 1/2 Recruiting
Clinical Trials
181 trialsNCT04039607 2026-02-19
CheckMate 9DW
Bristol-Myers Squibb
Phase 3 Active not recruiting
NCT05669339 2026-02-18
AD HOC Trial: Artificial Intelligence-Based Drug Dosing In Hepatocellular Carcinoma
University of Florida
Phase 2 Recruiting
NCT03211416 2026-02-05
Sorafenib Tosylate and Pembrolizumab in Treating Patients With Advanced or Metastatic Liver Cancer
Roswell Park Cancer Institute
Phase 1/2 Completed
NCT01730937 2026-01-28
Sorafenib Tosylate With or Without Stereotactic Body Radiation Therapy in Treating Patients With Liver Cancer
Radiation Therapy Oncology Group
Phase 3 Completed
NCT03298451 2026-01-14
HIMALAYA
AstraZeneca
Phase 3 Active not recruiting
NCT01658878 2025-12-24
CheckMate040
Bristol-Myers Squibb
Phase 1/2 Completed
NCT03755791 2025-12-11
COSMIC-312
Exelixis
Phase 3 Active not recruiting
NCT05033522 2025-10-23
ALIVE
Mirror Biologics, Inc.
Phase 2/3 Suspended
NCT03412773 2025-10-14
A Study of Tislelizumab Versus Sorafenib in Participants With Unresectable Hepatocellular Carcinoma (HCC)
BeiGene
Phase 3 Completed
NCT05822752 2025-08-14
LIVIGNO-1
AbbVie
Phase 2 Active not recruiting
NCT01754987 2025-05-04
A Study of Vitamin C in the Treatment of Liver Cancer to Determine if it is Safe and Effective
Thomas Jefferson University
Phase 1/2 Completed
NCT01840592 2025-05-02
Sorafenib Plus Doxorubicin in Patients With Advanced Hepatocellular Carcinoma With Disease Progression on Sorafenib
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT03899428 2025-03-24
Immune Checkpoint Therapy vs Target Therapy in Reducing Serum HBsAg Levels in Patients With HBsAg+ Advanced Stage HCC
Humanity & Health Medical Group Limited
Phase 2 Recruiting
NCT06797427 2025-03-17
A Study to Assess the Pharmacokinetics of Sorafenib in Mesoporous Magnesium Carbonate (DPH001) Compared to Nexavar® (sorafenib) in Healthy Volunteers
Disruptive Pharma
Phase EARLY_PHASE1 Completed
NCT02716012 2025-03-10
OUTREACH
Mina Alpha Limited
Phase 1 Unknown
NCT04710641 2025-03-06
OUTREACH2
Mina Alpha Limited
Phase 2 Completed
NCT02576509 2025-02-17
An Investigational Immuno-therapy Study of Nivolumab Compared to Sorafenib as a First Treatment in Patients With Advanced Hepatocellular Carcinoma
Bristol-Myers Squibb
Phase 3 Completed
NCT03439891 2025-02-11
Sorafenib and Nivolumab in Treating Participants With Unresectable, Locally Advanced or Metastatic Liver Cancer
University of California, San Francisco
Phase 2 Completed
NCT03009461 2024-12-04
Sorafenib Plus Hepatic Arterial Infusion Versus Sorafenib for HCC with Major Portal Vein Tumor Thrombosis
Peking University
Phase 2 Completed
NCT02143401 2024-11-22
Navitoclax and Sorafenib Tosylate in Treating Patients With Relapsed or Refractory Solid Tumors
National Cancer Institute (NCI)
Phase 1 Completed
NCT03606590 2024-11-14
Effect of Tumor Treating Fields (TTFields, 150kHz) Concomitant with Sorafenib for Advanced Hepatocellular Carcinoma (HCC) (HEPANOVA)
NovoCure Ltd.
Phase 2 Completed
NCT01906216 2024-08-28
SELECT
Air Force Military Medical University, China
Phase 3 Completed
NCT06527495 2024-07-30
Clinical Pharmacogenetic Study of Sorafenib in Egyptian Patients With Hepatocellular Carcinoma
Assiut University
Phase 1/2 Recruiting
NCT02856126 2024-07-23
HAIC Plus Sorafenib Versus TACE Plus Sorafenibfor Advanced HCC
Sun Yat-sen University
Phase 3 Completed
NCT04518852 2024-06-25
TACE, Sorafenib and PD-1 Monoclonal Antibody in the Treatment of HCC
Sichuan Cancer Hospital and Research Institute
Phase 2 Completed
NCT06030895 2024-03-12
Sorafenib In Egyptian Patients With Hepatocellular Carcinoma.
Damanhour University
Phase NA Completed
NCT04560894 2024-02-01
HCC
Sinocelltech Ltd.
Phase 2/3 Unknown
NCT01004978 2024-01-03
Chemoembolization With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Phase 3 Completed
NCT01624285 2023-12-14
Sorafenib Tosylate Following a Liver Transplant in Treating Patients With Liver Cancer
Jonsson Comprehensive Cancer Center
Phase 2 Completed
NCT02279719 2023-11-15
A Study of BBI608 in Combination With Sorafenib, or BBI503 in Combination With Sorafenib in Adult Patients With Hepatocellular Carcinoma
Sumitomo Pharma America, Inc.
Phase 1/2 Completed
NCT03434379 2023-10-23
IMbrave150
Hoffmann-La Roche
Phase 3 Completed
NCT04135690 2023-08-15
HAIC Plus Toripalimab vs. HAIC Plus Sorafenib for HCC With PVTT: a Non-comparative, Prospective, Randomized Trial
Sun Yat-sen University
Phase 2 Unknown
NCT03722498 2023-07-11
Phase â…¡ Study of HAIC of FOLFOX vs. Sorafenib in HCC Refractory to TACE
Sun Yat-sen University
Phase 2 Withdrawn
NCT04992143 2023-02-16
TACE+Tilelizumab+Sorafenib in the Treatment of BCLC Stage C HCC
First Affiliated Hospital of Zhejiang University
Phase 2 Unknown
NCT03236649 2023-02-08
The Phase III Study of Icaritin Versus Sorafenib in PD-L1 Positive Advanced Hepatocellular Carcinoma Subjects
Beijing Shenogen Biomedical Co., Ltd
Phase 3 Terminated
NCT03582618 2023-01-10
CVM-1118 and Sorafenib Combination in Subjects With Advanced Hepatocellular Carcinoma
TaiRx, Inc.
Phase 2 Terminated
NCT04720716 2022-09-19
A Study to Compare the Effectiveness and Safety of IBI310 Combined With Sintilimab Versus Sorafenib in the First-line Treatment of Advanced HCC
Innovent Biologics (Suzhou) Co. Ltd.
Phase 3 Unknown
NCT01988493 2022-08-24
Efficacy, Safety, and Pharmacokinetic of MSC2156119J in Asian Participants With Hepatocellular Carcinoma
Merck KGaA, Darmstadt, Germany
Phase 1/2 Completed
NCT01015833 2022-08-04
Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer
National Cancer Institute (NCI)
Phase 3 Completed
NCT02575339 2022-07-26
MLN0128 Compared to Sorafenib in Advanced or Metastatic Hepatocellular Carcinoma
Big Ten Cancer Research Consortium
Phase 1/2 Terminated
NCT05391867 2022-05-26
Assessment of the Efficacy of Lenvatinib Versus Sorafenib in the Management of Advanced Hepatocellular Carcinoma
Sir Salimullah Medical College Mitford Hospital
Phase NA Unknown
NCT04465734 2022-05-05
A Clinical Study to Compare the Efficacy and Safety of HLX10 in Combination With HLX04 Versus Sorafenib as the First-line Treatment in Patients With Locally Advanced or Metastatic HCC
Shanghai Henlius Biotech
Phase 3 Withdrawn
NCT02794337 2022-04-27
TACE-SBRT
Tata Memorial Hospital
Phase 2/3 Unknown
NCT00867321 2022-04-19
Bevacizumab and Sorafenib as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Liver Cancer
Alliance for Clinical Trials in Oncology
Phase 1/2 Completed
NCT02358395 2022-04-12
A Study of BBI608 Administrated With Sorafenib in Adult Patients With Advanced Hepatocellular Carcinoma
Sumitomo Pharma Co., Ltd.
Phase 1 Completed
NCT01761266 2022-04-05
A Multicenter, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-line Treatment of Participants With Unresectable Hepatocellular Carcinoma
Eisai Inc.
Phase 3 Completed
NCT01900002 2021-12-30
Sorafenib Tosylate and Yttrium Y 90 Glass Microspheres in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery
M.D. Anderson Cancer Center
Phase 2 Completed
NCT05121571 2021-11-26
The Efficacy and Safety of HAIC With FOLFOX vs Sorafenib for Patients Who Showed TACE-resistant: a Retrospective Study
Sun Yat-sen University
Phase NA Completed
NCT00844883 2021-11-11
Study of Sorafenib and Transarterial Chemoembolization (TACE) to Treat Hepatocellular Carcinoma
Yale University
Phase 2 Completed